• Profile
Close

Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis

Therapeutics and Clinical Risk Management Dec 25, 2018

Suzuki T, et al. - In postmenopausal osteoporosis (OP) patients with rheumatoid arthritis (RA), researchers compared the outcomes of bisphosphonate-pretreated denosumab therapy with or without vitamin D and calcium supplementation. They also assessed bone mineral density (BMD) of the lumbar 1–4 vertebrae (L-BMD) and bilateral total hips (H-BMD) at the same time points. For this 3-year retrospective study, 58 patients under long-term denosumab treatment were divided into groups without (denosumab group; 31 cases) or with (combination group; 27 cases) vitamin D and calcium supplementation. No significant differences were found in the percent changes of serum albumin-corrected calcium between the groups. The combination group displayed significantly increased serum zinc, L-BMD, and H-BMD at 3 years in OP patients with RA compared to denosumab monotherapy. Calcium and vitamin D supplementation may, therefore, be beneficial to enhance BMD gains, but not necessarily 25-hydroxyvitamin D status, in patients with denosumab OP and RA.
Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay